verapamil has been researched along with Asymmetric Septal Hypertrophy, Familial in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because sudden cardiac death is the most serious complication of HCM, particularly in young and asymptomatic patients, it follows that correct diagnosis, followed by risk stratification of patients with regard to the need for prophylactic implantation of an implantable cardiac defibrillator (ICD), can be of life-saving importance." | 2.47 | The diagnosis and treatment of hypertrophic cardiomyopathy. ( Faber, L; Farr, M; Hering, D; Horstkotte, D; Prinz, C, 2011) |
| " Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population." | 1.39 | Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. ( Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, P | 1 |
| Lan, F | 1 |
| Lee, AS | 1 |
| Gong, T | 1 |
| Sanchez-Freire, V | 1 |
| Wang, Y | 1 |
| Diecke, S | 1 |
| Sallam, K | 1 |
| Knowles, JW | 1 |
| Wang, PJ | 1 |
| Nguyen, PK | 1 |
| Bers, DM | 1 |
| Robbins, RC | 1 |
| Wu, JC | 1 |
| Prinz, C | 1 |
| Farr, M | 1 |
| Hering, D | 1 |
| Horstkotte, D | 1 |
| Faber, L | 1 |
1 review available for verapamil and Asymmetric Septal Hypertrophy, Familial
| Article | Year |
|---|---|
The diagnosis and treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Cardiac Surgical Procedures; Cardiomyopathy, Hypertr | 2011 |
1 other study available for verapamil and Asymmetric Septal Hypertrophy, Familial
| Article | Year |
|---|---|
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentia | 2013 |